. Author manuscript; available in PMC: 2019 Jun 1.

Published in final edited form as: Br J Haematol. 2018 Apr 19;181(5):642–652. doi: 10.1111/bjh.15251

Table III.

Comparison between BCR/ABL1-like and non-BCR/ABL1-like ALL cases included in the screening panel.

	BCR/ABL1-like	non-BCR/ABL1-like	p-value
JAK/STAT pathway members mutated cases	12/27 (44.4%)^{^}	10/107 (9.3%)	p<0.001

JAK1/2 mutations	7/27 (25.9%)	4/107 (3.7%)	p=0.001
CRLF2 mutations	2/27 (7.4%)	2/107 (1.9%)	ns
IL7R mutations	4/27 (14.8%)	4/107 (3.7%)	p=0.05

RAS pathway members mutated cases	6/27 (22.2%)	32/107 (29.9%)^*	ns

FLT3 mutations	0	9/107 (8.4%)	ns
KRAS/NRAS mutations	6/27 (22.2%)	24/107 (22.4%)	ns
IKZF1 deletions	14/18 (77.7%)	23/62 (37.1%)	p=0.029
EBF1 deletions	6/18 (33.3%)	4/62 (6.5%)	p=0.007
BTG1 deletions	4/18 (22.2%)	4/62 (6.5%)	p=0.071

CRLF2 overexpressing cases	16/28 (57.1%)	21/114 (18.4%)	p<0.001
CRLF2 median expression levels (range)	7.6 (2–16.6)	11.3 (3.2–17.5)	p<0.001

TK/cytokine receptor fusions	JAK2-fusions (N=1) TRIM24/FGFR1 (N=1) TSLP-fusions (N=2) 4/13 (30.7%)	P2RY8/CRLF2 (N=1) 1/21 (4.7%)	p=0.037

ns, not significant

^{^}

One case harboured IL7R and CRLF2 mutations

One 1 case harboured NRAS and FLT3 mutations